NDAORALTABLET, EXTENDED RELEASE
Approved
Nov 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BONJESTA is an oral extended-release tablet combining doxylamine succinate (a first-generation antihistamine) and pyridoxine hydrochloride (vitamin B6) indicated for nausea and vomiting of pregnancy (NVP). The combination leverages doxylamine's sedating antihistamine properties to reduce nausea while pyridoxine provides complementary symptom relief. This fixed-dose combination was the first FDA-approved product specifically for morning sickness in over 30 years.
$0.039BPart D
Peak6.3 years to LOEAt peak lifecycle with minimal competitive pressure, BONJESTA offers stable commercial opportunity but limited growth runway; team size likely stable with focus on market retention and adherence.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
Started May 2022
274 enrolled
Morning Sickness
Career Relevance
Working on BONJESTA offers stability within a niche, pregnancy-focused market with minimal competitive disruption but limited growth trajectory. Professionals will focus on provider engagement, payer relations, and safety monitoring in a specialized obstetric space rather than high-volume commercial expansion.
Brand Manager
Worked on BONJESTA at Duchesnay? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.